Haemonetics Corporation (HAE)

Days of sales outstanding (DSO)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Receivables turnover		12.57	11.46	13.74	13.40	12.97	6.15	—	—	6.20	—	—	—	6.76	6.01	6.37	6.69	5.99	5.86	5.60	5.99
DSO	days	29.04	31.85	26.57	27.24	28.14	59.33	—	—	58.91	—	—	—	54.00	60.76	57.31	54.53	60.92	62.28	65.15	60.96

March 31, 2024 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 12.57
= 29.04

The Days Sales Outstanding (DSO) ratio for Haemonetics Corporation has shown some fluctuations over the past few quarters. Generally, a lower DSO indicates a more efficient collection of accounts receivable, while a higher DSO suggests a slower collection process.

In the most recent quarter ending March 31, 2024, the DSO stood at 29.04 days, which is lower compared to the previous quarter's DSO of 31.85 days. This decrease indicates an improvement in the company's ability to collect revenue from customers.

Looking at the trend over the past few quarters, there has been some variability in the DSO ratio. In the quarter ending December 31, 2022, the DSO was significantly high at 59.33 days, indicating a delay in collecting receivables. However, the company seems to have improved this metric since then.

It is worth noting that for some quarters, data is missing, making it difficult to assess the trend consistently. In general, a company should aim to maintain a balance in its DSO, ensuring timely collection of receivables without putting undue pressure on customers.

Overall, based on the available data, Haemonetics Corporation has shown some improvement in its DSO, reflecting a potentially more effective accounts receivable management strategy.